A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Trial Identifier: D4190C00022
Sponsor: MedImmune, LLC
NCTID:: NCT02519348
Start Date: October 2015
Primary Completion Date: November 2020
Study Completion Date: March 2025
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
Italian Translation
Japanese Translation
Korean Translation
Malay Translation
Simplified Chinese Translation
Simplified Chinese Translation
Spanish Translation
Traditional Chinese Translation
Traditional Chinese Translation

Trial Locations

Country Location
CN Hangzhou, CN, 310016
CN Nanjing, CN, 210002
CN Shanghai, CN, 200032
ES Barcelona, ES, 08035
ES Barcelona, ES, 08036
ES Cordoba, ES, 14004
ES Pamplona, ES, 31008
HK Hong Kong, HK
HK Hong Kong, HK, -
HK Sha Tin, HK
IT Benevento, IT, 82100
IT Milano, IT, 20133
IT Roma, IT, 00168
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 277-8577
JP Osakasayama-shi, JP, 589-8511
KR Busan, KR, 49241
KR Jung-gu, KR, 41944
KR Seongnam-si, KR, 13620
KR Seoul, KR, 03080
KR Seoul, KR, 06351
KR Seoul, KR, 06273
KR Seoul, KR, 05505
SG Bukit Merah, SG, 169610
SG Singapore, SG, 119074
SG Singapore, SG, 308433
TW Kaohsiung City, TW, 83301
TW Taipei, TW, 100
TW Taoyuan City, TW, 333
US, AZ Phoenix, AZ, US, 85054
US, CA San Francisco, CA, US, 94158
US, CT New Haven, CT, US, 06510
US, FL Jacksonville, FL, US, 32224
US, FL Tampa, FL, US, 33612
US, IN Indianapolis, IN, US, 46202
US, MA Boston, MA, US, 02114
US, NC Durham, NC, US, 27705
US, NY New York, NY, US, 10065
US, NY Stony Brook, NY, US, 11794
US, OR Portland, OR, US, 97213
US, PA Philadelphia, PA, US, 19111
US, PA Philadelphia, PA, US, 19107
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75390
US, WA Seattle, WA, US, 98109